"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Down Syndrome"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Alzheimer Disease"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Down Syndrome"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Alzheimer Disease"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Down Syndrome"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056329"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0039"::"NCT00056329"::"Vitamin E in Aging Persons With Down Syndrome"::""::"Multicenter Vitamin E Trial in Aging Persons With Down Syndrome"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"350"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Alzheimer Disease"::"Brief Praxis Test, measuring cognitive functions expressed as performances of simple, short, sequences of voluntary movements"::"Screening, Baseline, every 6 months for 36 months"::"No"::"Vitamin E"
"NCT00056472"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"U01 MH62624"::"NCT00056472"::"Study of Pharmacotherapy of Psychotic Depression"::"STOP-PD"::"Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression"::"National Institute of Mental Health (NIMH)"::"National Institute of Mental Health (NIMH)"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"259"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Major Depression With Psychotic Features"::"Remission of depression (Hamilton Depression Scale) and psychosis (Schedule for Affective Disorders in Schizophrenia - delusional item) during the course of the trial"::"Weeks 1-6, 8, 10, 12"::"No"::"Olanzapine"
"NCT00081471"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16738"::"NCT00081471"::"A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis"::""::"A Randomized, Open-Label Study of the Effect of Subcutaneous Mircera on Hemoglobin Level/Correction in Non-Dialysis Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"324"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Hemoglobin response rate"::"Weeks 1-28"::"No"::"Darbepoetin alfa"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Toxicity"::""::"Yes"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Incidence of tumor lysis syndrome"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Response rate"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Incidence of tumor lysis syndrome"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Response rate"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Cyclophosphamide"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Methotrexate"
"NCT00057811"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000271941"::"NCT00057811"::"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma"::""::"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment"::"2"::"0"::"90"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Lymphoma"::"Minimal residual disease"::""::"No"::"Prednisone"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Event-free survival"::""::"No"::"Vinblastine"
"NCT00059839"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000298777"::"NCT00059839"::"Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma"::""::"A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"200"::""::""::"Both"::"N/A"::"20 Years"::"No"::"Lymphoma"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Cisplatin"
"NCT00061893"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000302409"::"NCT00061893"::"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors"::""::"A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment"::"4"::"0"::"36"::""::""::"Both"::"N/A"::"50 Years"::"No"::"Sarcoma"::"Feasibility as measured by  toxicity at study completion"::""::"Yes"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Cisplatin"
"NCT00075582"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000347078"::"NCT00075582"::"Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma"::""::"Vincristine, Dactinomycin, And Lower Doses Of Cyclophosphamide With or Without Radiation Therapy For Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"360"::""::""::"Both"::"N/A"::"49 Years"::"No"::"Sarcoma"::"Failure-free survival"::""::"No"::"Vinblastine"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Cyclophosphamide"
"NCT00075725"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000349182"::"NCT00075725"::"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"::""::"High Risk B-Precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"4"::"0"::"2964"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Improvement of the treatment outcome"::""::"No"::"Methotrexate"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"ERBB2 protein expression in patients with progression-free survival   2 years after study completion"::""::"No"::"Cisplatin"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"ERBB2 protein expression in patients with progression-free survival   2 years after study completion"::""::"No"::"Vinblastine"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Effects of a computer-based training system compared to the current standard of care  as measured by reading decoding composite score 2 years after study completion"::""::"No"::"Cisplatin"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Effects of a computer-based training system compared to the current standard of care  as measured by reading decoding composite score 2 years after study completion"::""::"No"::"Vinblastine"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Treatment failure in the posterior fossa of patients undergoing reduced-dose radiotherapy  approximately 2 years after study completion"::""::"No"::"Cisplatin"
"NCT00085202"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000367486"::"NCT00085202"::"Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::""::"Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor"::"St. Jude Children's Research Hospital"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"2"::"0"::"164"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Treatment failure in the posterior fossa of patients undergoing reduced-dose radiotherapy  approximately 2 years after study completion"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Cisplatin"
"NCT00085735"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000365506"::"NCT00085735"::"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"::""::"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"6"::"0"::"455"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to event as measured by the time to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm at   3 years"::""::"No"::"Vinblastine"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00087178"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000372952"::"NCT00087178"::"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer"::""::"A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"2"::"0"::"2700"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"DFS or no breast cancer (BC) at time of  local recurrence (LR) following mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death from any cause prior to recurrence"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cisplatin"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Vinblastine"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00103285"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000409589"::"NCT00103285"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Standard Risk B-precursor Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"7"::"0"::"3381"::""::""::"Both"::"1 Year"::"9 Years"::"No"::"Leukemia"::"Event-free survival (EFS)"::""::"No"::"Cyclophosphamide"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00232180"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6141079"::"NCT00232180"::"A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines"::"EMPHASIS-HF"::"The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure"::"Pfizer"::"Pfizer"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Heart Failure"::"Cardiovascular mortality or heart failure hospitalization"::"5 years"::"No"::"Eplerenone"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00245154"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000450850"::"NCT00245154"::"Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer"::""::"A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer"::"NCIC Clinical Trials Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"2"::"0"::"750"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Lung Cancer"::"Progression-free survival"::""::"No"::"Oxaliplatin"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00254904"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A8501002"::"NCT00254904"::"Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC"::""::"International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Terminated"::"\
    See Termination Reason in Detailed Description\
  "::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"839"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall Survival"::"656 Events"::"No"::"Gemcitabine"
"NCT00262847"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000455114"::"NCT00262847"::"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::""::"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::"Gynecologic Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"3"::"0"::"2000"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Fallopian Tube Cancer"::"Progression-free survival measured by RECIST Criteria and Modified Rustin Criteria for CA-125 at baseline, prior to every other course of therapy, every 3 months for 2 years, every 6 months for 3 years, and then annually during follow-up"::""::"No"::"Oxaliplatin"
"NCT00262847"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000455114"::"NCT00262847"::"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::""::"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::"Gynecologic Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"3"::"0"::"2000"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Ovarian Cancer"::"Progression-free survival measured by RECIST Criteria and Modified Rustin Criteria for CA-125 at baseline, prior to every other course of therapy, every 3 months for 2 years, every 6 months for 3 years, and then annually during follow-up"::""::"No"::"Oxaliplatin"
"NCT00262847"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000455114"::"NCT00262847"::"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::""::"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer, or Fallopian Tube Cancer"::"Gynecologic Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind, Placebo Control"::"3"::"0"::"2000"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Peritoneal Cavity Cancer"::"Progression-free survival measured by RECIST Criteria and Modified Rustin Criteria for CA-125 at baseline, prior to every other course of therapy, every 3 months for 2 years, every 6 months for 3 years, and then annually during follow-up"::""::"No"::"Oxaliplatin"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00326898"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000478976"::"NCT00326898"::"Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery"::""::"ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma"::"Eastern Cooperative Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double-Blind"::"3"::"0"::"1923"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Cancer"::"Disease-free survival"::""::"No"::"Sulindac"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free and overall survival"::""::"No"::"Vinblastine"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Cisplatin"
"NCT00335556"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000472893"::"NCT00335556"::"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors"::""::"Treatment of High Risk Renal Tumors"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Open Label"::"6"::"0"::"295"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Antitumor activity"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Overall survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Overall survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Overall survival at 2 years"::""::"No"::"Vinblastine"
"NCT00335738"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483043"::"NCT00335738"::"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma"::""::"A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized"::"2"::"0"::"600"::""::""::"Both"::"N/A"::"6 Years"::"No"::"Retinoblastoma"::"Overall survival at 2 years"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Cisplatin"
"NCT00336024"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000483683"::"NCT00336024"::"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma"::""::"A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"96"::""::""::"Both"::"N/A"::"2 Years"::"No"::"Brain and Central Nervous System Tumors"::"Complete response by 3-dimensional tumor measurements"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Overall survival at 4 years"::""::"No"::"Vinblastine"
"NCT00352534"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487540"::"NCT00352534"::"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor"::""::"Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"600"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Kidney Cancer"::"Event-free survival at 4 years"::""::"No"::"Vinblastine"
"NCT00372437"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"0103-006"::"NCT00372437"::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::""::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::"MethylGene Inc."::"MethylGene Inc."::"Completed"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Tumors"::"Maximum tolerated dose in combination with azacitidine"::"1 year (anticipated)"::"Yes"::"Gemcitabine"
"NCT00372437"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"0103-006"::"NCT00372437"::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::""::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::"MethylGene Inc."::"MethylGene Inc."::"Completed"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Tumors"::"Response rate"::"1 year (anticipated)"::"No"::"Gemcitabine"
"NCT00372437"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"0103-006"::"NCT00372437"::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::""::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::"MethylGene Inc."::"MethylGene Inc."::"Completed"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Tumors"::"Maximum tolerated dose in combination with azacitidine"::"1 year (anticipated)"::"Yes"::"Gemcitabine"
"NCT00372437"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"0103-006"::"NCT00372437"::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::""::"A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine"::"MethylGene Inc."::"MethylGene Inc."::"Completed"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Tumors"::"Response rate"::"1 year (anticipated)"::"No"::"Gemcitabine"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cyclophosphamide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Etoposide"
"NCT00372593"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000487497"::"NCT00372593"::"Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia"::""::"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"1000"::""::""::"Both"::"N/A"::"29 Years"::"No"::"Leukemia"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Efficacy of therapy"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cisplatin"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Vinblastine"
"NCT00381680"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000495359"::"NCT00381680"::"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia"::""::"Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"418"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Cisplatin"
"NCT00392327"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000511991"::"NCT00392327"::"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor"::""::"Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"4"::"0"::"300"::""::""::"Both"::"3 Years"::"21 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival (e.g., events comprising disease progression or recurrence, occurrence of a second malignant neoplasm, or death from any cause)"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Toxicity"::""::"Yes"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Time to tumor progression, disease recurrence, or death of any cause"::""::"No"::"Vinblastine"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Cisplatin"
"NCT00392886"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000503990"::"NCT00392886"::"Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors"::""::"Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]"::"Children's Hospital Los Angeles"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment"::"2"::"0"::"120"::""::""::"Both"::"N/A"::"10 Years"::"No"::"Brain and Central Nervous System Tumors"::"Event-free survival at 2 years"::""::"No"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Drug/Agent Toxicity by Tissue/Organ"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Cisplatin"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Methotrexate"
"NCT00400946"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000513019"::"NCT00400946"::"Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"Treatment of Acute Lymphoblastic Leukemia in Children"::"Dana-Farber Cancer Institute"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"544"::""::""::"Both"::"1 Year"::"17 Years"::"No"::"Leukemia"::"Toxicity of pegasparaginase vs E. coli asparaginase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Event-free survival after initial remission"::""::"No"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Toxicity of nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of combination chemotherapy with vs without nelarabine"::""::"Yes"::"Vinblastine"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Cisplatin"
"NCT00408005"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000514500"::"NCT00408005"::"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::""::"Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Active Control"::"16"::"0"::"1380"::""::""::"Both"::"1 Year"::"30 Years"::"No"::"Leukemia"::"Safety and efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine  vs escalating-dose methotrexate (without leucovorin calcium rescue) and  pegaspargase"::""::"Yes"::"Vinblastine"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00408408"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000515432"::"NCT00408408"::"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery"::""::"A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens"::"National Surgical Adjuvant Breast and Bowel Project (NSABP)"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"6"::"0"::"1200"::""::""::"Female"::"18 Years"::"N/A"::"No"::"Breast Cancer"::"Pathologic complete response (pCR) of the primary tumor in the breast"::""::"No"::"Cisplatin"
"NCT00430183"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000526353"::"NCT00430183"::"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer"::""::"Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer"::"Cancer and Leukemia Group B"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"750"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"3-year biochemical progression-free survival (bPFS) rate"::""::"No"::"Cyclophosphamide"
"NCT00430183"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000526353"::"NCT00430183"::"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer"::""::"Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer"::"Cancer and Leukemia Group B"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"750"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"3-year biochemical progression-free survival (bPFS) rate"::""::"No"::"Cyclophosphamide"
"NCT00430183"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000526353"::"NCT00430183"::"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer"::""::"Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer"::"Cancer and Leukemia Group B"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"750"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"3-year biochemical progression-free survival (bPFS) rate"::""::"No"::"Cyclophosphamide"
"NCT00430183"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000526353"::"NCT00430183"::"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer"::""::"Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer"::"Cancer and Leukemia Group B"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"750"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"3-year biochemical progression-free survival (bPFS) rate"::""::"No"::"Cyclophosphamide"
"NCT00430183"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000526353"::"NCT00430183"::"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer"::""::"Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer"::"Cancer and Leukemia Group B"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"750"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"3-year biochemical progression-free survival (bPFS) rate"::""::"No"::"Cyclophosphamide"
"NCT00456599"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"UMCC 2006.025"::"NCT00456599"::"Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer"::""::"A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer"::"University of Michigan Cancer Center"::"University of Michigan Cancer Center"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment"::"0"::"0"::"68"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pancreatic Cancer"::"Two-year disease free survival."::""::""::"Gemcitabine"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Overall survival"::""::"No"::"Cisplatin"
"NCT00499616"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000554708"::"NCT00499616"::"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma"::""::"Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label"::"3"::"0"::"395"::""::""::"Both"::"N/A"::"12 Years"::"No"::"Neuroblastoma"::"Event-free survival"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Feasibility of administering bevacizumab with chemotherapy"::""::"Yes"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Time to progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for disease progression"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for death"::""::"No"::"Vinblastine"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Cisplatin"
"NCT00516295"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000560873"::"NCT00516295"::"Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma"::""::"A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label"::"2"::"0"::"78"::""::""::"Both"::"1 Year"::"29 Years"::"No"::"Sarcoma"::"Risk for second malignant neoplasm"::""::"No"::"Vinblastine"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Methotrexate"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Cyclophosphamide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Etoposide"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Prednisone"
"NCT00557193"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000573996"::"NCT00557193"::"Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia"::""::"A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"3"::"0"::"244"::""::""::"Both"::"N/A"::"1 Year"::"No"::"Leukemia"::"Event-free survival at 3 years"::""::"No"::"Lenalidomide"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Event-free survival rate"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Response after induction therapy"::""::"No"::"Magnesium Sulfate"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Cisplatin"
"NCT00567567"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000576571"::"NCT00567567"::"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma"::""::"Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma"::"Children's Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 3"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"495"::""::""::"Both"::"N/A"::"30 Years"::"No"::"Neuroblastoma"::"Incidence rate of local recurrence"::""::"No"::"Magnesium Sulfate"
"NCT00653120"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"40451"::"NCT00653120"::"Bioavailability Study of Propranolol Under Fasting Conditions"::""::"Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions."::"Par Pharmaceutical, Inc."::"Par Pharmaceutical, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Other, Randomized, Open Label, Crossover Assignment"::"2"::"0"::"48"::""::""::"Both"::"18 Years"::"N/A"::"Accepts Healthy Volunteers"::"To Determine Bioequivalence Under Fasting Conditions"::"Rate and Extend of Absorption"::"24 Hours"::"No"::"Propranolol"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Successful delivery of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) treatment using the Codetronô unit (phase II)"::""::"No"::"Prednisone"
"NCT00656513"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000592644"::"NCT00656513"::"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer"::""::"A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Suspended"::""::"Phase 2/Phase 3"::"Interventional"::"Supportive Care, Randomized"::"2"::"0"::"189"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Xerostomia"::"Overall xerostomia burden at  9 months after randomization, as measured by the University of Michigan 15-item Xerostomia Related Quality of Life Scale (XeQOLS) (phase III)"::""::"No"::"Prednisone"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00658775"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"E3810-G000-302"::"NCT00658775"::"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::""::"A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)"::"Eisai Inc."::"Eisai Inc."::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1060"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Gastroesophageal Reflux Disease (GERD)"::"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment."::"Every 4-8 weeks."::"No"::"Esomeprazole"
"NCT00720083"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CDR0000599867"::"NCT00720083"::"Chemotherapy and Radiation Therapy With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer"::""::"A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck"::"Radiation Therapy Oncology Group"::"National Cancer Institute (NCI)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized"::"2"::"0"::"170"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Cancer"::"Progression-free survival"::""::"No"::"Tretinoin"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Time to disease progression."::"Every 6 weeks for 30 weeks, and then every 9 weeks.  Assessments continue until disease progression."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Breast Neoplasms"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00732810"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"P04716"::"NCT00732810"::"SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)"::""::"A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers"::"Schering-Plough"::"Schering-Plough"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"6"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Overall response rate in subjects treated with SCH 727965 after disease progression on the comparator drug."::"Every 6 weeks for 30 weeks, and then every 9 weeks."::"No"::"Erlotinib"
"NCT00741156"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000012255"::"NCT00741156"::"The Acute Effects of the Angiotensin-Converting Enzyme Inhibitor Enalaprilat on Flow Distribution"::""::"The Acute Effects of the Angiotensin-Converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"15"::""::""::"Both"::"2 Months"::"5 Years"::"No"::"Hypertension"::"The acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary, and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients."::"This outcome will be measured following the cardiac catheterization procedure (~20 mins after drug is administered)"::"No"::"Enalapril"
"NCT00741156"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000012255"::"NCT00741156"::"The Acute Effects of the Angiotensin-Converting Enzyme Inhibitor Enalaprilat on Flow Distribution"::""::"The Acute Effects of the Angiotensin-Converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"15"::""::""::"Both"::"2 Months"::"5 Years"::"No"::"Congestive Cardiomyopathy"::"The acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary, and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients."::"This outcome will be measured following the cardiac catheterization procedure (~20 mins after drug is administered)"::"No"::"Enalapril"
"NCT00755690"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"H08-01018"::"NCT00755690"::"Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease"::""::"Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease"::"University of British Columbia"::"University of British Columbia"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study"::"3"::"0"::"30"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Kidney Diseases"::"FGF-23"::"5 days"::"No"::"Losartan"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00098306"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A4001027"::"NCT00098306"::"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects"::"MOTIVATE 1"::"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2/Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"601"::""::""::"Both"::"16 Years"::"N/A"::"No"::"HIV Infections"::"Change from baseline in log10 HIV-1 RNA, measured at 24 and 48 weeks."::"Week 24 and 48"::"No"::"Doxazosin"
"NCT00105235"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"DAIT ITN024ST"::"NCT00105235"::"Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients"::"TILT"::"A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"27"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Liver Disease"::"Proportion of participants who have graft loss or death"::"Within 1 year of transplantation"::"Yes"::"Mycophenolate mofetil"
"NCT00105235"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"DAIT ITN024ST"::"NCT00105235"::"Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients"::"TILT"::"A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"27"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Liver Transplantation"::"Proportion of participants who have graft loss or death"::"Within 1 year of transplantation"::"Yes"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00115791"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"04-7-010"::"NCT00115791"::"Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::""::"A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"276"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm"::"Infusion plus 1.5 hours"::"No"::"Mycophenolate mofetil"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Hydrocortisone"
"NCT00136435"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"01-175"::"NCT00136435"::"A Study in Adults With Untreated Acute Lymphoblastic Leukemia"::""::"A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"100"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, safety and efficacy of the high-risk pediatric treatment regimen in adult patients between the ages of 18 and 50 years"::"TBD"::"Yes"::"Vincristine"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Osteoarthritis"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"any event that in clinical practice would impact the subject in terms of inpatient/outpatient investigation for GI pathology with blood loss or other serious complication"::"6 months"::"Yes"::"Celecoxib"
"NCT00141102"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3191084"::"NCT00141102"::"Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis"::"CONDOR"::"Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"4627"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthritis, Rheumatoid"::"The incidence of clinically significant upper and/or lower GI events (CSULGIEs)"::"6 months"::"Yes"::"Celecoxib"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00259519"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"N041000314"::"NCT00259519"::"Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes"::""::"Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial"::"University of Alberta"::"University of Alberta"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study"::"2"::"0"::"360"::""::""::"Female"::"N/A"::"N/A"::"No"::"Fetal Membranes, Premature Rupture"::"Length of Stay in hospital"::"time between birth and readiness for discharge"::"No"::"Propofol"
"NCT00281554"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"05-7-012"::"NCT00281554"::"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation"::"ACT 4"::"A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"254"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00281554"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"05-7-012"::"NCT00281554"::"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation"::"ACT 4"::"A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"254"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00281554"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"05-7-012"::"NCT00281554"::"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation"::"ACT 4"::"A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"254"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00281554"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"05-7-012"::"NCT00281554"::"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation"::"ACT 4"::"A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"254"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00281554"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"05-7-012"::"NCT00281554"::"Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation"::"ACT 4"::"A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"254"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute"::"Infusion plus 1.5 hours"::"No"::"Prednisone"
"NCT00282347"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"U2970g"::"NCT00282347"::"A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis (LUNAR)"::"LUNAR"::"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis"::"Genentech"::"Genentech"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment"::"2"::"0"::"140"::""::""::"Both"::"16 Years"::"75 Years"::"No"::"Lupus Nephritis"::"Proportion of subjects who achieve a renal response"::"52 weeks"::"No"::"Irinotecan"
"NCT00314639"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"4764"::"NCT00314639"::"Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia"::""::"The Impact of Modafinil as an Adjunctive to a Second Generation Antipsychotic on Cognitive Functioning in Schizophrenia and Schizophrenia Spectrum Psychosis."::"Laval University"::"Laval University"::"Completed"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study"::"1"::"0"::"30"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Schizophrenia and Schizophrenia Spectrum Psychosis"::"Neuropsychological assessments"::"Pre and post Modafinil and Placebo Phases (Days 0, 28, 42 and 70)"::""::"Modafinil"
"NCT00358995"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"B02-0132"::"NCT00358995"::"A Cognitive Behavioral Therapy of Primary Obsessions in Obsessive Compulsive Disorder"::""::"A New Cognitive Behavioral Therapy to Target Distorted Appraisals Characteristic of Primary Obsessions in Obsessive Compulsive Disorder"::"University of British Columbia"::"University of British Columbia"::"Active, not recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"100"::""::""::"Both"::"18 Years"::"65 Years"::"No"::"Obsessive Compulsive Disorder"::"The primary outcome of the study is to determine if CBT is more effective than SMT in reducing distorted beliefs and OCD symptoms in study participants post treatment, as well as six and twelve months post treatment."::"12 months"::"No"::"Pentoxifylline"
"NCT00370604"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1-PAngle"::"NCT00370604"::"Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study"::""::"Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache"::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"N/A"::"Interventional"::"Prevention, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Female"::"18 Years"::"N/A"::"Accepts Healthy Volunteers"::"Post-Dural Puncture Headache"::"Incidence of postdural puncture headache"::"within the first 14 days of epidural placement"::"Yes"::"Cisplatin"
"NCT00370604"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1-PAngle"::"NCT00370604"::"Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study"::""::"Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache"::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"N/A"::"Interventional"::"Prevention, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Female"::"18 Years"::"N/A"::"Accepts Healthy Volunteers"::"Post-Dural Puncture Headache"::"Incidence of postdural puncture headache"::"within the first 14 days of epidural placement"::"Yes"::"Cisplatin"
"NCT00370604"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1-PAngle"::"NCT00370604"::"Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study"::""::"Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache"::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"N/A"::"Interventional"::"Prevention, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Female"::"18 Years"::"N/A"::"Accepts Healthy Volunteers"::"Post-Dural Puncture Headache"::"Incidence of postdural puncture headache"::"within the first 14 days of epidural placement"::"Yes"::"Cisplatin"
"NCT00370604"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1-PAngle"::"NCT00370604"::"Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study"::""::"Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache"::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"N/A"::"Interventional"::"Prevention, Randomized, Single Blind (Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"3100"::""::""::"Female"::"18 Years"::"N/A"::"Accepts Healthy Volunteers"::"Post-Dural Puncture Headache"::"Incidence of postdural puncture headache"::"within the first 14 days of epidural placement"::"Yes"::"Cisplatin"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00376701"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R-06-441"::"NCT00376701"::"Combination Therapy for Age-Related Macular Degeneration."::""::"Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin."::"Lawson Health Research Institute"::"Lawson Health Research Institute"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study"::"3"::"0"::"103"::""::""::"Both"::"50 Years"::"N/A"::"No"::"Age Related Macular Degeneration"::"To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy."::"1 year"::"No"::"Triamcinolone"
"NCT00380068"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AMB-323"::"NCT00380068"::"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::""::"ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::"Gilead Sciences"::"Gilead Sciences"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pulmonary Hypertension"::"The primary endpoint of this study is the change from baseline in 6MWD."::"Week 24"::"No"::"Simvastatin"
"NCT00380068"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AMB-323"::"NCT00380068"::"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::""::"ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::"Gilead Sciences"::"Gilead Sciences"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pulmonary Hypertension"::"The primary endpoint of this study is the change from baseline in 6MWD."::"Week 24"::"No"::"Simvastatin"
"NCT00380068"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AMB-323"::"NCT00380068"::"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::""::"ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::"Gilead Sciences"::"Gilead Sciences"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pulmonary Hypertension"::"The primary endpoint of this study is the change from baseline in 6MWD."::"Week 24"::"No"::"Simvastatin"
"NCT00380068"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AMB-323"::"NCT00380068"::"Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::""::"ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension"::"Gilead Sciences"::"Gilead Sciences"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"200"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pulmonary Hypertension"::"The primary endpoint of this study is the change from baseline in 6MWD."::"Week 24"::"No"::"Simvastatin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00412984"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CV185-030"::"NCT00412984"::"Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation"::"ARISTOTLE"::"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"18183"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Flutter"::"confirmed stroke or systemic embolism"::"Time to first occurrence"::"Yes"::"Warfarin"
"NCT00429364"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"461"::"NCT00429364"::"Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network"::""::"Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)"::"National Heart, Lung, and Blood Institute (NHLBI)"::"National Heart, Lung, and Blood Institute (NHLBI)"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"604"::""::""::"Both"::"6 Months"::"25 Years"::"No"::"Marfan Syndrome"::"Rate of change in aortic root (sinuses of Valsalva) body-surface-area-adjusted Z-score"::"Measured at Month 36"::"No"::"Losartan"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Mycophenolate mofetil"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00431041"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"VES-001"::"NCT00431041"::"Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)"::"VECTOR"::"VECTOR: A Randomized Double-Blind Study to Assess the Safety and Efficacy of Solifenacin (VesicareÆ) in Comparison to Oxybutynin for Overactive Bladder Patients"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"132"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Overactive Bladder"::"Safety of solifenacin as compared to oxybutynin IR in patients with OAB symptoms"::"8 weeks"::"Yes"::"Prednisone"
"NCT00456599"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"UMCC 2006.025"::"NCT00456599"::"Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer"::""::"A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer"::"University of Michigan Cancer Center"::"University of Michigan Cancer Center"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment"::"0"::"0"::"68"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Pancreatic Cancer"::"Two-year disease free survival."::""::""::"Oxaliplatin"
"NCT00468403"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"DAIT CIT-04"::"NCT00468403"::"LEA29Y (Belatacept) Emory Edmonton Protocol"::"LEEP"::"Islet Transplantation in Type I Diabetes With LEA29Y (Belatacept) Maintenance Therapy"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"National Institute of Allergy and Infectious Diseases (NIAID)"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"20"::""::""::"Both"::"18 Years"::"65 Years"::"No"::"Type 1 Diabetes Mellitus"::"Proportion of participants with insulin independence"::"75 days after first islet transplant"::"No"::"Fluticasone Propionate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Methotrexate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Methotrexate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Methotrexate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Methotrexate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Methotrexate"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00476190"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"06-254"::"NCT00476190"::"ALL Adult Consortium Trial: Adult ALL Trial"::""::"ALL Adult Consortium Trial: Adult ALL Trial"::"Dana-Farber Cancer Institute"::"Dana-Farber Cancer Institute"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Historical Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"60"::""::""::"Both"::"18 Years"::"50 Years"::"No"::"Acute Lymphoblastic Leukemia"::"To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older."::"3 years"::"Yes"::"Vincristine"
"NCT00482989"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MI-CP152"::"NCT00482989"::"A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus"::""::"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus"::"MedImmune LLC"::"MedImmune LLC"::"Active, not recruiting"::""::"Phase 1"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety Study"::"2"::"0"::"157"::""::""::"Both"::"18 Years"::"95 Years"::"No"::"Lupus"::"The safety and tolerability of MEDI-545 will be assessed primarily by summarizing AEs and by assessing changes in viral cultures and titers."::"Through Study Day 350."::"Yes"::"Propofol"
"NCT00493428"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"B2006:156"::"NCT00493428"::"Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study"::""::"Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study"::"University of Manitoba"::"University of Manitoba"::"Suspended"::"\
    The study have been stoped because the protocol is going to be modify.\
  "::"Phase 2"::"Interventional"::"Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"70 Years"::"No"::"Hepatocellular Carcinoma"::"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization."::"6 years"::"Yes"::"Dextromethorphan"
"NCT00493428"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"B2006:156"::"NCT00493428"::"Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study"::""::"Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study"::"University of Manitoba"::"University of Manitoba"::"Suspended"::"\
    The study have been stoped because the protocol is going to be modify.\
  "::"Phase 2"::"Interventional"::"Treatment, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"47"::""::""::"Both"::"18 Years"::"70 Years"::"No"::"Hepatocellular Carcinoma"::"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization."::"6 years"::"Yes"::"Dextromethorphan"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 1: determine maximum tolerated dose"::"every cycle"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 1: determine maximum tolerated dose"::"every cycle"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 1: determine maximum tolerated dose"::"every cycle"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 1: determine maximum tolerated dose"::"every cycle"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 2: overall survival"::"baseline to date of death from any cause"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 2: overall survival"::"baseline to date of death from any cause"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 2: overall survival"::"baseline to date of death from any cause"::"Yes"::"Cisplatin"
"NCT00529100"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"10259"::"NCT00529100"::"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer"::""::"A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study"::"1"::"0"::"39"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Non-small Cell Lung Cancer"::"Phase 2: overall survival"::"baseline to date of death from any cause"::"Yes"::"Cisplatin"
"NCT00531466"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AV650-014"::"NCT00531466"::"Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury"::""::"AV650-014: A Four Week, Prospective, Randomized, Double Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV650 in Patients With Spasticity Due to Spinal Cord Injury"::"Avigen"::"Avigen"::"Terminated"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"120"::""::""::"Both"::"18 Years"::"70 Years"::"No"::"Muscle Spasticity"::"To assess the safety, tolerability and PK profile of AV650 in subjects with spasticity due to spinal cord injury."::"1 month"::"Yes"::"Ribavirin"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Coronary Artery Disease (CAD)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00543400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"MOM-M118-006"::"NCT00543400"::"Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)"::"EMINENCE"::"A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy"::"Momenta Pharmaceuticals, Inc."::"Momenta Pharmaceuticals, Inc."::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment"::"2"::"0"::"503"::""::""::"Both"::"19 Years"::"N/A"::"No"::"Percutaneous Coronary Intervention (PCI)"::"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding."::"30 days"::"No"::"Methylphenidate"
"NCT00594568"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"7666"::"NCT00594568"::"Effect of LY450139 on the Long Term Progression of Alzheimer's Disease"::""::"Effect of -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"1500"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Alzheimer's Disease"::"Rate of cognitive and functional decline in Alzheimer's disease over time."::"Throughout the study"::"No"::"Cyclophosphamide"
"NCT00594568"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"7666"::"NCT00594568"::"Effect of LY450139 on the Long Term Progression of Alzheimer's Disease"::""::"Effect of -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"1500"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Alzheimer's Disease"::"Rate of cognitive and functional decline in Alzheimer's disease over time."::"Throughout the study"::"No"::"Cyclophosphamide"
"NCT00594568"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"7666"::"NCT00594568"::"Effect of LY450139 on the Long Term Progression of Alzheimer's Disease"::""::"Effect of -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"1500"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Alzheimer's Disease"::"Rate of cognitive and functional decline in Alzheimer's disease over time."::"Throughout the study"::"No"::"Cyclophosphamide"
"NCT00594568"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"7666"::"NCT00594568"::"Effect of LY450139 on the Long Term Progression of Alzheimer's Disease"::""::"Effect of -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo"::"Eli Lilly and Company"::"Eli Lilly and Company"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"1500"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Alzheimer's Disease"::"Rate of cognitive and functional decline in Alzheimer's disease over time."::"Throughout the study"::"No"::"Cyclophosphamide"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of total venous thromboembolisms (VTE)."::"6 Weeks"::"No"::"Warfarin"
"NCT00595426"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"150-CL-033"::"NCT00595426"::"A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement"::"PEARL"::"A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty"::"Astellas Pharma Inc"::"Astellas Pharma Inc"::"Completed"::""::"Phase 2"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"5"::"0"::"685"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Arthroplasty, Replacement, Knee"::"The incidence of bleeding events classified as major by the Adjudication Committee"::"6 Weeks"::"No"::"Warfarin"
"NCT00640991"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RECREATE Pilot"::"NCT00640991"::"REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)"::"RECREATE Pilot"::"An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study"::"Population Health Research Institute"::"Population Health Research Institute"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment"::"2"::"0"::"500"::""::""::"Both"::"N/A"::"N/A"::"No"::"Hyperglycemia"::"The 24-hour difference in mean glucose between the two study groups."::"24 hours"::"No"::"Adenosine"
"NCT00640991"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RECREATE Pilot"::"NCT00640991"::"REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)"::"RECREATE Pilot"::"An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study"::"Population Health Research Institute"::"Population Health Research Institute"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment"::"2"::"0"::"500"::""::""::"Both"::"N/A"::"N/A"::"No"::"Cardiovascular Diseases"::"The 24-hour difference in mean glucose between the two study groups."::"24 hours"::"No"::"Adenosine"
"NCT00640991"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RECREATE Pilot"::"NCT00640991"::"REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)"::"RECREATE Pilot"::"An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study"::"Population Health Research Institute"::"Population Health Research Institute"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment"::"2"::"0"::"500"::""::""::"Both"::"N/A"::"N/A"::"No"::"Myocardial Infarction"::"The 24-hour difference in mean glucose between the two study groups."::"24 hours"::"No"::"Adenosine"
"NCT00697632"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"265-101"::"NCT00697632"::"Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies"::""::"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies"::"MethylGene Inc."::"MethylGene Inc."::"Recruiting"::""::"Phase 1"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study"::"1"::"0"::"60"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Malignancies"::"Safety and tolerability"::"1 year [Anticipated]"::"Yes"::"Prednisone"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Esophagogastric Junction Adenocarcinoma"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Gastric Cancer"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Esophagogastric Junction Adenocarcinoma"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Gastric Cancer"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Esophageal Cancer"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00719550"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20060317"::"NCT00719550"::"AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer"::""::"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102"::"Amgen"::"Amgen"::"Recruiting"::""::"Phase 1/Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety/Efficacy Study"::"4"::"0"::"136"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Esophageal Cancer"::"Progression free survival (PFS), as measured by RECIST per local review"::"Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study."::"No"::"Alendronate"
"NCT00744536"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RV-MDS-PI-128"::"NCT00744536"::"Efficacy Study of RevlimidÆ and Low Dose Continuously Administered Melphalan to Treat Higher Risk Myelodysplastic Syndromes"::"REMMYDYS"::"RevlimidÆ, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study\""::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study"::"1"::"0"::"20"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Myelodysplastic Syndromes"::"Overall Response Rate (RR) (as defined by modified international working group standardized response criteria)"::"1.5 years"::"No"::"Lenalidomide"
"NCT00744536"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RV-MDS-PI-128"::"NCT00744536"::"Efficacy Study of RevlimidÆ and Low Dose Continuously Administered Melphalan to Treat Higher Risk Myelodysplastic Syndromes"::"REMMYDYS"::"RevlimidÆ, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study\""::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study"::"1"::"0"::"20"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Leukemia, Myelomonocytic, Chronic"::"Overall Response Rate (RR) (as defined by modified international working group standardized response criteria)"::"1.5 years"::"No"::"Lenalidomide"
"NCT00744536"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"RV-MDS-PI-128"::"NCT00744536"::"Efficacy Study of RevlimidÆ and Low Dose Continuously Administered Melphalan to Treat Higher Risk Myelodysplastic Syndromes"::"REMMYDYS"::"RevlimidÆ, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study\""::"Sunnybrook Health Sciences Centre"::"Sunnybrook Health Sciences Centre"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study"::"1"::"0"::"20"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Angiogenesis"::"Overall Response Rate (RR) (as defined by modified international working group standardized response criteria)"::"1.5 years"::"No"::"Lenalidomide"
"NCT00048152"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M67005"::"NCT00048152"::"A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients"::""::"A Randomized, Open-Label Study Comparing the Effects of Low-Dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"539"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Transplantation"::"Renal function (as measured by GFR)"::"12 months post-transplant"::"No"::"Verteporfin"
"NCT00048152"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M67005"::"NCT00048152"::"A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients"::""::"A Randomized, Open-Label Study Comparing the Effects of Low-Dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"539"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Transplantation"::"Renal function (as measured by GFR)"::"12 months post-transplant"::"No"::"Verteporfin"
"NCT00048152"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M67005"::"NCT00048152"::"A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients"::""::"A Randomized, Open-Label Study Comparing the Effects of Low-Dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"539"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Transplantation"::"Renal function (as measured by GFR)"::"12 months post-transplant"::"No"::"Verteporfin"
"NCT00048152"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M67005"::"NCT00048152"::"A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients"::""::"A Randomized, Open-Label Study Comparing the Effects of Low-Dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"539"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Kidney Transplantation"::"Renal function (as measured by GFR)"::"12 months post-transplant"::"No"::"Verteporfin"
"NCT00065507"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-048"::"NCT00065507"::"Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation"::""::"Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"220"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Hepatitis B"::"Mean serum HBV DNA PCR adjusted for baseline"::"at Week 24"::"No"::"Entecavir"
"NCT00065507"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-048"::"NCT00065507"::"Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation"::""::"Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"220"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Hepatitis B"::"Mean serum HBV DNA PCR adjusted for baseline"::"at Week 24"::"No"::"Entecavir"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00077610"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BA16739"::"NCT00077610"::"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients"::""::"A Randomized, Open-Label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Level/Correction in Patients With Chronic Kidney Disease"::"Hoffmann-La Roche"::"Hoffmann-La Roche"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"673"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Anemia"::"Change in hemoglobin concentration"::"Weeks 1-36"::"No"::"Ibandronate"
"NCT00086281"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"OMC-SXB-23"::"NCT00086281"::"Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients"::""::"Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients"::"Orphan Medical"::"Orphan Medical"::"Completed"::""::"Phase 4"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study"::"4"::"0"::"60"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Obstructive Sleep Apnea Syndrome"::"The primary efficacy variable was the AHI, determined from the polysomnogram (PSG). The AHI was defined as the incidence (events per hour) of apnea and hypopnea events associated with sleep."::"One night of PSG during one night of treatment each per arm."::"Yes"::"Zolpidem"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Hepatitis B"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Hepatitis B"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Hepatitis B"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Chronic Disease"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Chronic Disease"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00096785"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"AI463-079"::"NCT00096785"::"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection"::""::"Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"69"::""::""::"Both"::"16 Years"::"N/A"::"No"::"Chronic Disease"::"Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR(log10 copies/mL)"::"at Week 12 adjusted for baseline"::"No"::"Entecavir"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Chronic Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Philadelphia-Positive Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Chronic Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Philadelphia-Positive Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Chronic Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Philadelphia-Positive Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Chronic Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00103844"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"CA180-017"::"NCT00103844"::"Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia"::""::"A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d"::"Bristol-Myers Squibb"::"Bristol-Myers Squibb"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study"::"2"::"0"::"151"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Philadelphia-Positive Myeloid Leukemia"::"To estimate the major cytogenetic response (MCyR) rates of BMS-354825 and imatinib at 800 mg daily"::"at 12 weeks"::"No"::"Imatinib"
"NCT00152347"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"C05-0384"::"NCT00152347"::"A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot"::""::"A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot"::"University of British Columbia"::"University of British Columbia"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study"::"1"::"0"::"72"::""::""::"Both"::"N/A"::"2 Months"::"No"::"Idiopathic Clubfoot (Talipes Equinovarus)"::"Primary Outcome:  Response to study treatment (as indicated by ankle dorsiflexion with knee in flexion of 15 degrees or greater)"::"Unspecified"::"No"::"Dexmedetomidine"
"NCT00174837"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"EFC5512"::"NCT00174837"::"TRACE: Tirapazamine-Radiation And Cisplatin Evaluation"::"TRACE"::"Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer"::"Sanofi-Aventis"::"Sanofi-Aventis"::"Completed"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"317"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Head and Neck Squamous Cell Carcinoma"::"Overall survival"::"Study period"::"No"::"Oxaliplatin"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Atherosclerosis"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Atherosclerosis"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Cardiovascular Diseases"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Cardiovascular Diseases"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Hypercholesterolemia"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Hypercholesterolemia"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Hypertension"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Hypertension"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Diabetes Mellitus"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Diabetes Mellitus"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Coronary Disease"::"Cognitive decline:  rate of decline in tests of memory and executive function in the glycemic treatment group"::"Baseline, 20 months and 40 months"::"No"::"Disulfiram"
"NCT00182910"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"IA0080"::"NCT00182910"::"ACCORD-MIND: Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::""::"Action to Control Cardiovascular Risk in Diabetes--Memory in Diabetes"::"National Institute on Aging (NIA)"::"National Institute on Aging (NIA)"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Active Control, Factorial Assignment, Efficacy Study"::"6"::"0"::"2977"::""::""::"Both"::"55 Years"::"N/A"::"No"::"Coronary Disease"::"MRI brain changes:  total brain volume (cerebral atrophy) in the glycemic treatment group"::"Baseline and 40 months"::"No"::"Disulfiram"
"NCT00247897"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"C05-0389"::"NCT00247897"::"Comparing Skin Disinfectants Before Labour Epidural Analgesia"::""::"What is the Best Skin Preparation Solution for Labour Epidural Analgesia? A Randomized Prospective Trial Comparing ChloraprepTM, DuraprepTM, and Chlorhexidine 0.5% in 70% Alcohol."::"University of British Columbia"::"University of British Columbia"::"Recruiting"::""::"N/A"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Single Group Assignment, Efficacy Study"::"1"::"0"::"195"::""::""::"Female"::"N/A"::"N/A"::"Accepts Healthy Volunteers"::"Skin Bacteria"::"25% reduction in skin bacterial colony counts at time of epidural catheter removal"::"Unspecified"::"No"::"Etoposide"
"NCT00264498"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1839IL/0551"::"NCT00264498"::"Phase II Iressa & Carbo/Gem in NSCLC"::""::"A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSAô) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"38"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Progression Free Survival (PFS)"::"Date of randomization to earliest date of objective disease progression"::"No"::"Erlotinib"
"NCT00265317"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6181058"::"NCT00265317"::"A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone"::"SUN1058"::"Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"165"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Radiographic progression of disease"::"From screening until disease progression or discontinuation of study."::"No"::"Erlotinib"
"NCT00265317"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6181058"::"NCT00265317"::"A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone"::"SUN1058"::"Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"165"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Radiographic progression of disease"::"From screening until disease progression or discontinuation of study."::"No"::"Erlotinib"
"NCT00265317"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6181058"::"NCT00265317"::"A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone"::"SUN1058"::"Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"165"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Radiographic progression of disease"::"From screening until disease progression or discontinuation of study."::"No"::"Erlotinib"
"NCT00265317"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A6181058"::"NCT00265317"::"A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone"::"SUN1058"::"Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer"::"Pfizer"::"Pfizer"::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"165"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Carcinoma, Non-Small-Cell Lung"::"Radiographic progression of disease"::"From screening until disease progression or discontinuation of study."::"No"::"Erlotinib"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00278889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00041"::"NCT00278889"::"Second Line ColoRectal Cancer Therapy in Combination With FOLFOX"::"HORIZON I"::"A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"231"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"To compare the efficacy of AZD2171 in combination with FOLFOX with bevacizumab in combination with FOLFOX.  This objective will be assessed by the primary variable of progression free survival (PFS)"::"time to progression; time to death"::"No"::"Irinotecan"
"NCT00283400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R01NS049135"::"NCT00283400"::"Treatment of Subarachnoid Hemorrhage With Human Albumin"::""::"Treatment of Subarachnoid Hemorrhage With Human Albumin"::"Baylor College of Medicine"::"Baylor College of Medicine"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment"::"4"::"0"::"80"::""::""::"Both"::"18 Years"::"79 Years"::"No"::"Subarachnoid Hemorrhage"::"Safety and tolerability of the 25% HA dosages and the functional outcome.  Tolerability outcome:  Subject's ability to receive the full allocated HA dose without incurring frank congestive heart failure or experiencing anaphylactic reactions that require"::"15 days after enrollment"::"Yes"::"Clopidogrel"
"NCT00283400"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"R01NS049135"::"NCT00283400"::"Treatment of Subarachnoid Hemorrhage With Human Albumin"::""::"Treatment of Subarachnoid Hemorrhage With Human Albumin"::"Baylor College of Medicine"::"Baylor College of Medicine"::"Recruiting"::""::"N/A"::"Interventional"::"Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment"::"4"::"0"::"80"::""::""::"Both"::"18 Years"::"79 Years"::"No"::"Subarachnoid Hemorrhage"::"Safety and tolerability of the 25% HA dosages and the functional outcome.  Tolerability outcome:  Subject's ability to receive the full allocated HA dose without incurring frank congestive heart failure or experiencing anaphylactic reactions that require"::"15 days after enrollment"::"Yes"::"Clopidogrel"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"overall survival"::"one year"::"No"::"Gemcitabine"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Cisplatin"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Erlotinib"
"NCT00349219"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"TORCH"::"NCT00349219"::"TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer"::"TORCH"::"An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer"::"National Cancer Institute, Naples"::"National Cancer Institute, Naples"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"900"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Advanced Non-Small Cell Lung Cancer"::"progression free rate of first-line treatment with erlotinib"::"after 9 weeks of treatment"::"Yes"::"Gemcitabine"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Leucovorin"
"NCT00384176"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D8480C00013"::"NCT00384176"::"First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX"::"HORIZON III"::"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTINô, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer"::"AstraZeneca"::"AstraZeneca"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1614"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Colorectal Cancer"::"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."::"assessed after each visit over 15 months"::"No"::"Oxaliplatin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Atrial Fibrillation"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Composite of major and non-major clinically relevant bleeding events"::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00403767"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"11630"::"NCT00403767"::"Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation"::""::"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation"::"Bayer"::"Bayer"::"Active, not recruiting"::""::"Phase 3"::"Interventional"::"Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"14266"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Stroke"::"Any stroke or non-CNS systemic embolism."::"1 day up to 4 years"::"No"::"Warfarin"
"NCT00457457"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3711044"::"NCT00457457"::"Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms."::""::"A Multi-Center, Randomized, Parallel Group, Double-Blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"609"::""::""::"Male"::"40 Years"::"N/A"::"No"::"Prostatic Hyperplasia"::"Change in international prostate symptom score"::"12 weeks"::"No"::"Tamsulosin"
"NCT00457457"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3711044"::"NCT00457457"::"Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms."::""::"A Multi-Center, Randomized, Parallel Group, Double-Blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"609"::""::""::"Male"::"40 Years"::"N/A"::"No"::"Prostatic Hyperplasia"::"Change in international prostate symptom score"::"12 weeks"::"No"::"Tamsulosin"
"NCT00457457"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"A3711044"::"NCT00457457"::"Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms."::""::"A Multi-Center, Randomized, Parallel Group, Double-Blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)"::"Pfizer"::"Pfizer"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"609"::""::""::"Male"::"40 Years"::"N/A"::"No"::"Prostatic Hyperplasia"::"Change in international prostate symptom score"::"12 weeks"::"No"::"Tamsulosin"
"NCT00463229"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"PHE-78692"::"NCT00463229"::"Interdisciplinary Team Approach to Stroke Rehabilitation in Home Care"::""::"The Comparative Acceptability, Safety, Effects and Expense of Specialized, Integrated, and Interdisciplinary Community Rehabilitation for Stroke Survivors and Their Caregivers"::"Hamilton Health Sciences"::"McMaster University"::"Active, not recruiting"::""::"Phase 1"::"Interventional"::"Treatment, Randomized, Double Blind (Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study"::"2"::"0"::"102"::""::""::"Both"::"N/A"::"N/A"::"No"::"Stroke"::"SF-36 Health Survey"::"20 minutes"::"No"::"Lamotrigine"
"NCT00468936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"BMB 06-006"::"NCT00468936"::"Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms"::""::"Open-Label, Randomized Study Comparing the Patient Reported Severity of GI Side Effects of MMF Versus EC-MPS in Maintenance Heart Transplant Patients."::"McGill University Health Center"::"McGill University Health Center"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"100"::""::""::"Both"::"18 Years"::"N/A"::"No"::"Heart Transplant Patients"::"reduction in GSRS score"::"6 months"::"Yes"::"Entecavir"
"NCT00484536"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"C32322"::"NCT00484536"::"Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323"::""::"Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323."::"UCB, Inc."::"UCB, Inc."::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"279"::""::""::"Both"::"18 Years"::"55 Years"::"No"::"Multiple Sclerosis"::"To compare the effects of CDP323 on MS-related imaging parameters in subjects with relapsing MS (RMS) with the effects seen under placebo treatment in that population"::"24 weeks"::"No"::"Fluoxetine"
"NCT00484536"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"C32322"::"NCT00484536"::"Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323"::""::"Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323."::"UCB, Inc."::"UCB, Inc."::"Active, not recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"3"::"0"::"279"::""::""::"Both"::"18 Years"::"55 Years"::"No"::"Multiple Sclerosis"::"To compare the effects of CDP323 on MS-related imaging parameters in subjects with relapsing MS (RMS) with the effects seen under placebo treatment in that population"::"24 weeks"::"No"::"Fluoxetine"
"NCT00502788"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"503"::"NCT00502788"::"Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)"::"HepC"::"Thalassemia Clinical Research Network - Hepatitis C Clinical Trial"::"National Heart, Lung, and Blood Institute (NHLBI)"::"National Heart, Lung, and Blood Institute (NHLBI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study"::"1"::"0"::"21"::""::""::"Both"::"18 Years"::"44 Years"::"No"::"Hepatitis C"::"Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)"::"Measured at Week 72"::"Yes"::"Ribavirin"
"NCT00502788"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"503"::"NCT00502788"::"Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)"::"HepC"::"Thalassemia Clinical Research Network - Hepatitis C Clinical Trial"::"National Heart, Lung, and Blood Institute (NHLBI)"::"National Heart, Lung, and Blood Institute (NHLBI)"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study"::"1"::"0"::"21"::""::""::"Both"::"18 Years"::"44 Years"::"No"::"Thalassemia"::"Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)"::"Measured at Week 72"::"Yes"::"Ribavirin"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathy, Painful"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Polyneuropathy"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathy, Painful"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Polyneuropathy"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathy, Painful"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Polyneuropathy"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathy, Painful"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Polyneuropathy"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Neuralgia, Diabetic"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuralgia"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathies"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Neuralgia, Diabetic"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuralgia"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathies"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Neuralgia, Diabetic"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuralgia"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathies"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Neuralgia, Diabetic"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuralgia"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00507936"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"M06-850"::"NCT00507936"::"Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain"::""::"A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain"::"Abbott"::"Abbott"::"Completed"::""::"Phase 2"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study"::"5"::"0"::"280"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Diabetic Neuropathies"::"Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP"::"Change from baseline to final 24-hour average pain score"::"No"::"Duloxetine"
"NCT00563316"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20062010"::"NCT00563316"::"Panitumumab DDI Irinotecan"::""::"A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer"::"Amgen"::"Amgen"::"Active, not recruiting"::""::"Phase 1"::"Interventional"::"Treatment, Open Label, Single Group Assignment, Pharmacokinetics Study"::"1"::"0"::"23"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Metastatic Colorectal Cancer"::"Cmax and AUC of irinotecan with and without concomitant panitumumab administration"::"July 30, 2009 (18 months)"::"No"::"Irinotecan"
"NCT00563316"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"20062010"::"NCT00563316"::"Panitumumab DDI Irinotecan"::""::"A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer"::"Amgen"::"Amgen"::"Active, not recruiting"::""::"Phase 1"::"Interventional"::"Treatment, Open Label, Single Group Assignment, Pharmacokinetics Study"::"1"::"0"::"23"::""::""::"Both"::"18 Years"::"75 Years"::"No"::"Metastatic Colorectal Cancer"::"Cmax and AUC of irinotecan with and without concomitant panitumumab administration"::"July 30, 2009 (18 months)"::"No"::"Irinotecan"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00575796"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"1000011227"::"NCT00575796"::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::""::"Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)"::"The Hospital for Sick Children"::"The Hospital for Sick Children"::"Recruiting"::""::"Phase 2"::"Interventional"::"Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study"::"1"::"0"::"50"::""::""::"Both"::"1 Year"::"18 Years"::"No"::"Glioma"::"The response rate to weekly vinblastine"::"70 Weeks"::"No"::"Vinblastine"
"NCT00616889"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"PSIY-206-05"::"NCT00616889"::"Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder"::""::"Effects of Seroquel on Sleep Architecture in Patients With Bipolar Depression or Major Depressive Disorder - An Open Label Study"::"Queen's University"::"Queen's University"::"Completed"::""::"Phase 1"::"Observational"::"Cohort, Prospective"::"0"::"1"::"15"::"None Retained"::"Non-Probability Sample"::"Both"::"18 Years"::"65 Years"::"No"::"Bipolar Disorder"::"Sleep quality as measured by overnight PSG."::"baseline, day 2 to 4 (early) and day 21 to 28 (longer term). Optional reading at day 42-56"::"No"::"Cyclophosphamide"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"
"NCT00626548"::"Canada"::"Information obtained from ClinicalTrials.gov on December 30, 2009"::"D4320C00015"::"NCT00626548"::"A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer"::"ENTHUSE M0"::"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients"::"AstraZeneca"::"AstraZeneca"::"Recruiting"::""::"Phase 3"::"Interventional"::"Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study"::"2"::"0"::"1500"::""::""::"Male"::"18 Years"::"N/A"::"No"::"Prostate Cancer"::"Progression-free survival and Overall survival"::"Assessed  at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks"::"No"::"Estradiol"